Keryx Biopharma (KERX) Misses Q4 EPS by 7c

Keryx Biopharma (NASDAQ: KERX) reported Q4 EPS of ($0.32), $0.07 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $8.41 million.

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• SanDisk upgraded at JPMorgan after investor day; shares climb